MedTrace Logo

Towards Reducing Resistance and Hematological Toxicity of Linezolid

NCT00177723 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2008-12-17

No results posted yet for this study

Summary

The study will evaluate and improve the performance of pharmaco-statistical models previously developed in the compassionate use program in patients being treated with linezolid under clinical usage conditions. This study will also develop a sensitive and specific tool that may be used to predict patients at risk of hematological toxicity, based on factors including linezolid concentration and duration of therapy and use these models to better understand the determinants of toxicity with linezolid and define better strategies to manage toxicity or reduce its occurrence.

Conditions

Sponsors & Collaborators

Principal Investigators

  • David L Paterson, MD · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00177723 on ClinicalTrials.gov